This inventor holds 7 USPTO granted patents and 7 published patent applications and 4 EPO patents. Top assignees: Storm Therapeutics Limited, Padlock Therapeutics, Inc., Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 2018-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Abingdon, GB (2018 - 2021)
- Oxfordshire, GB (2023)
Company Filing History:
4 out of 4 
2 out of 6 
1 out of 1,335 
Years Active: 2018-2026
Title: Mark Peter Ridgill: Innovator in PAD4 Inhibition
Introduction
Mark Peter Ridgill, an accomplished inventor based in Abingdon, GB, has made significant contributions to the field of biochemical research with his innovative patents. With a portfolio of three patents, Ridgill specializes in developing compounds that inhibit PAD4, a target for treating PAD4-related disorders.
Latest Patents
Ridgill's latest patents reflect his expertise in this specialized area. His notable inventions include:
1. **Heteroaryl Inhibitors of PAD4** - This invention provides compounds that are useful as inhibitors of PAD4, along with compositions and methods for treating disorders related to PAD4.
2. **Bicyclic Inhibitors of PAD4** - Similar to his previous work, this patent presents compounds aimed at inhibiting PAD4, presenting methods and compositions for tackling PAD4-related ailments.
Career Highlights
Throughout his career, Mark Peter Ridgill has worked with notable organizations, including Padlock Therapeutics, Inc. and the Max Planck Society for the Advancement of Science. His tenure at these institutions has allowed him to hone his skills and develop groundbreaking innovations that address critical health issues.
Collaborations
Ridgill has collaborated with talented individuals in the field, including colleagues Mirco Meniconi and Heather Tye. Together, they have contributed to the innovative research landscape focused on PAD4 inhibitors.
Conclusion
Mark Peter Ridgill's work continues to push the boundaries of scientific understanding and innovation in the realm of PAD4 inhibition. His patents not only exemplify his dedication to improving health outcomes but also highlight the importance of collaboration in the research community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile